Who asks: the head of signal management at Calder Bay Pharma, a fictional company.
Why: the quarterly screen has flagged Lorvessa and tinnitus, and a signal analyst must decide, with numbers and cases, whether it goes forward for assessment.
The data: the quarterly screening counts on the left, the 9 cases behind them, and the Lorvessa label (Reference, then Products).
What done looks like: a validation note with the 2x2 table, the PRR, the ROR and its lower confidence limit, the screening rules checked, the number of distinct cases, the supportive cases, and a recommendation.
A project in eight steps on one screening hit. Each step adds to your worksheet; by the end you have the signal validation note a safety physician would sign.